Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug664 | Blood sampling (venesection) Wiki | 0.41 |
| drug1086 | Comparator full face mask 1 Wiki | 0.41 |
| drug4442 | Toffee Full Face Mask Wiki | 0.41 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1087 | Comparator full face mask 2 Wiki | 0.41 |
| drug3999 | Sleep Education Wiki | 0.41 |
| drug4144 | Standardised questionnaires Wiki | 0.41 |
| drug1088 | Comparator full face mask 3 Wiki | 0.41 |
| drug740 | CBT-OSA Wiki | 0.41 |
| drug666 | Blood test for IgG antibodies against SARS-CoV-2 Wiki | 0.41 |
| drug1916 | Home Sleep Apnea Testing or In-hospital Polysomnography Wiki | 0.41 |
| drug2319 | Lemborexant 10 mg Wiki | 0.29 |
| drug665 | Blood test Wiki | 0.29 |
| drug3195 | Placebo Wiki | 0.02 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D020181 | Sleep Apnea, Obstructive NIH | 1.00 |
| D012891 | Sleep Apnea, NIH | 0.83 |
| D001049 | Apnea NIH | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D008173 | Lung Diseases, Obstructive NIH | 0.10 |
| D029424 | Pulmonary Disease, Chronic Obstructive NIH | 0.09 |
| D009103 | Multiple Sclerosis NIH | 0.09 |
| D012598 | Scoliosi NIH | 0.09 |
| D012120 | Respiration Disorders NIH | 0.09 |
| D008171 | Lung Diseases, NIH | 0.07 |
| D040921 | Stress Disorders, Traumatic NIH | 0.07 |
| D013313 | Stress Disorders, Post-Traumatic NIH | 0.07 |
| D013577 | Syndrome NIH | 0.04 |
| D011014 | Pneumonia NIH | 0.02 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0010535 | Sleep apnea HPO | 0.83 |
| HP:0002104 | Apnea HPO | 0.71 |
| HP:0006536 | Pulmonary obstruction HPO | 0.10 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0006510 | Chronic pulmonary obstruction HPO | 0.09 |
| HP:0002088 | Abnormal lung morphology HPO | 0.07 |
| HP:0002090 | Pneumonia HPO | 0.02 |
Navigate: Correlations HPO
There are 6 clinical trials
Approximately 20 million Americans suffer from Obstructive Sleep Apnea (OSA) creating risks for major health problems, including dementia, heart attack, and stroke. Obesity, a growing problem for Americans and Veterans alike, is the greatest risk factor for the development of OSA. Male gender and smoking, other OSA risk factors, are common in Veterans. Given the high comorbidity of these risk factors in Veterans, OSA presents a significant health burden to Veterans. The investigators' prior work provides evidence that OSA occurs in up to 69% of Vietnam-era Veterans with PTSD. OSA is easily treated; however, 15-30% of OSA patients are non-compliant with continuous positive airway pressure (CPAP), the standard OSA treatment. The proposed research aims to facilitate adherence to CPAP treatment by testing a novel cognitive-behavioral therapy intervention in Veterans with PTSD. If successful, it may represent an approach that could be applied to the rehabilitation of other chronic conditions with similar barriers to care.
Description: The CPAP machine will measure the number of hours that the CPAP mask is on the participant's face and in use.
Measure: Time in hours of "mask-on" CPAP usage per night Time: 1 yearDescription: Effect of CBT on Self-reported Everyday Activities, Mood and Quality of Life. The investigators hypothesize that after initiating CPAP treatment, Veterans in the CBT-OSA group will report more improvement in the ease of performing everyday activities compared to that reported by those in the Education group.
Measure: Functional Outcomes of Sleep Questionnaire (FOSQ) Time: 1 yearDescription: Effect of CBT on Cognitive Outcomes. The CBT-OSA group will have better cognitive outcomes than the Education group over time. The California Verbal Learning Test-II, Delayed Recall Score is the cognitive outcome measure.
Measure: California Verbal Learning Test, Second Edition (CVLT-II) Time: 1 yearDescription: Effect of CBT on PTSD. The CBT-OSA group will have fewer PTSD symptoms than the Education group over time. The PTSD Checklist for DSM-5 (PCL-5) will be the PTSD outcome measure.
Measure: PTSD Checklist for DSM-5 (PCL-5) Time: 1 yearCovid-19 infection is an on-going pandemic with worse diagnosis in adults with comorbid conditions such as hypertension and cardiopulmonary diseases. Obstructive sleep apnea (OSA) is common in those comorbidities and may contribute to worse prognosis for the Covid-19 cases.
Description: Defined as a decline of 2 categories from admission on a 7-category ordinal scale
Measure: The rate of clinical improvement Time: 7 daysDescription: Defined as a decline of 2 categories from admission on a 7-category ordinal scale
Measure: The rate of clinical improvement Time: 14 daysDescription: Defined as a decline of 2 categories from admission on a 7-category ordinal scale
Measure: The rate of clinical improvement Time: 21 daysDescription: Defined as a decline of 2 categories from admission on a 7-category ordinal scale
Measure: The rate of clinical improvement Time: 28 daysDescription: Time to hospital discharge, ICU discharge, weaning from intubation, weaning from supplemental oxygen, incident pneumonia, ARDS, in-hospital mortality
Measure: Clinical status - improvement Time: 7, 14, 21, 28 daysDescription: Defined as an increase in category on a 7-category ordinal scale from admission
Measure: Clinical status - worsening Time: 7, 14, 21, 28 daysDescription: Re-analysis of the correlation of obstructive sleep apnea (objectively verified) severity in terms of apnea-hypopnea index and oxygenation levels with the primary and secondary outcomes as described above (the rate of clinical improvement defined as a decline of 2 categories from admission on a 7-category ordinal scale; time to hospital discharge, ICU discharge, weaning from intubation, weaning from supplemental oxygen, incident pneumonia, ARDS, in-hospital mortality as well as with the lung function, CO-diffusion capacity, cardiac function, CT thorax pathologies, biomarkers (cytokines, polymorphisms) and IgG-antibodies after 4 months.
Measure: Long-term outcomes Time: 4-6 months after the initial hospital admissionAs long as the people stay at home because of the Covid 19 outbreak, the investigators assume that the sleep quality of OUAS patients, like everyone else, and the sleep quality of COVID-19 outbreak are reduced due to anxiety and anxiety in people. In addition, we assume that sleep quality and physical activity level are related to health literacy level and fear of movement (kinesiophobia). In this study; the investigators aimed to determine how patients are affected by this process by evaluating sleep quality, physical activity, fear of movement and health literacy in OSAS patients during our stay in the COVID-19 outbreak.
Description: International Physical Activity Questionnaire/ In activity-specific scoring, walking under the heading of the fields is calculated by the sum of the moderate intensity activity and intensive activity in itself. From these calculations, a score is obtained in MET-minutes. There are 3 categories of physical activity level classification. Physical activity levels are classified as physically inactive (inactive), low level of physical activity (minimally active) and sufficient level of physical activity (very active)
Measure: Physical Activity Time: 1 dayDescription: The Pittsburgh Sleep Quality Index
Measure: Sleep Quality Time: 1 dayDescription: In order to measure the general sleepiness of people during the day, it was evaluated with a standard questionnaire, which is defined as Epworth sleepiness scale (EUS) and consists of 8 questions. The answers for each question are scored between 0 and 3 and the total score is obtained. The score obtained above 10 in EUS has high sensitivity and specificity for daytime sleepiness.
Measure: Daytime Sleepiness Time: 1 dayDescription: Tampa Kinesiophobia Scale (TKS)The person gets a total score between 17-68. The high score on the scale indicates that kinesiophobia is also high
Measure: Fear of movement Time: 1 dayDescription: Translated into Turkish TURKEY health literacy SCALE-32 (Tsoy-32) will be used. It was used to evaluate the literacy rates of individuals over the age of 15. 0 indicates the lowest health literacy and 50 indicates the highest health literacy.
Measure: Health literacy Time: 1 dayDescription: In the human circadian rhythm, the Morning Morning-Evening Survey (SAA) form was used, which determined morning and evening types.
Measure: Circadian rhythm evaluation Time: 1 dayThis study will evaluate the influence of sleep apnea on clinical and radiological features of MS. Sleep apnea is associated with hypoxemia during sleep, which we believe is detrimental to MS. We will examine clinical data (MRI, lab results, medical history, labs, and sleep studies) of Dr. Sloane's MS patients. This will allow us to study correlations between MRI, clinical data, lab studies and sleep studies. We are specifically interested in the type of sleep apnea associated with MS, and whether MRI or clinical metrics of MS severity correlate with presence or absence of sleep apnea.
Description: Home Sleep Study Data
Measure: Home Sleep Study Data Time: 1 yearDescription: sleep quality, quality of life, depression and anxiety scales
Measure: Questionnaire data Time: 1 yearThis will be a prospective, multi-arm, randomized, and non-blinded clinical trial designed to evaluate the performance, comfort, and usability of the Toffee full face mask amongst participants who have been prescribed PAP therapy by a physician. This clinical trial will take place across three investigation sites with a sample of 45 participants.
Description: To assess the comfort of the mask as experienced by the participant. Comfort will be measured on a 5 point likert type scale from Very Uncomfortable to Very Comfortable. Different aspects of the mask such as cushion comfort, headgear comfort and overall comfort will be assessed using the same scale. Questions will be asked on a questionnaire and further qualitative responses will be captured during an interview.
Measure: Comfort Time: Assessed 2 weeks after mask fittingDescription: To assess the ease of use of the mask as experienced by the participant. Questions regarding the ease of assembly, disassembly and mask fitting will be asked using a 5 point likert type scale with responses ranging from Very Easy to Very Difficult. Questions will be asked via a questionnaire with additional qualitative responses captured during an interview.
Measure: Usability Time: Assessed 2 weeks after mask fittingDescription: To assess the long term reliability and durability of the mask when used in a home. environment over an extended period of time. Open ended questions during a semi-structured interview will be asked to participants who will provide qualitative information on their experience using the mask with specific regard to broken or degraded parts and components.
Measure: Reliability and Durability Time: Assessed 4 months after mask fittingThe primary purpose of the study is to determine whether lemborexant increases the apnea hypopnea index (AHI) on Day 8 of treatment in adult and elderly participants (adults greater than or equal to [>=] 45 to less than [<] 65 years; elderly >=65 to 90 years) with moderate to severe obstructive sleep apnea (OSA) compared with placebo, and using pulse oximetry determine whether lemborexant decreases the peripheral oxygen saturation (SpO2) during total sleep time (TST) on Day 8 of treatment in adult and elderly participants (adults >=45 to <65 years; elderly >=65 to 90 years) with moderate to severe chronic obstructive pulmonary disease (COPD) compared with placebo.
Description: AHI is defined as the average number of apneas and hypopneas per hour of sleep. AHI will be assessed using polysomnography (PSG). The International Classification of Sleep Disorders (ICSD) (American Academy of Sleep Medicine, 2014) defines the severity of OSA according to the AHI: an AHI >5 to <15 is classed as mild, AHI >=15 to <30 as moderate, and AHI >=30 as severe.
Measure: OSA Cohort: AHI on Day 8 of Treatment Time: Day 8Description: SpO2 is an estimate of the amount of oxygen in the blood. It is the percentage of hemoglobin containing oxygen compared to the total amount of hemoglobin in the blood (that is, oxygenated hemoglobin versus oxygenated and non-oxygenated hemoglobin). SpO2 is monitored by noninvasive method known as transmissive pulse oximetry. TST is defined as the total time asleep in minutes using PSG.
Measure: COPD Cohort: Mean SpO2 During TST on Day 8 of Treatment Time: Day 8Description: AHI is defined as the average number of apneas and hypopneas per hour of sleep. AHI will be assessed using PSG. The ICSD (American Academy of Sleep Medicine, 2014) defines the severity of OSA according to the AHI: an AHI >5 to <15 is classed as mild, AHI >=15 to <30 as moderate, and AHI >=30 as severe.
Measure: AHI on Day 1 and Day 8 of Treatment Time: OSA Cohort: Day 1; COPD Cohort: Day 1 and Day 8Description: SpO2 is an estimate of the amount of oxygen in the blood. It is the percentage of hemoglobin containing oxygen compared to the total amount of hemoglobin in the blood (that is, oxygenated hemoglobin versus oxygenated and non-oxygenated hemoglobin). SpO2 is monitored by noninvasive method known as transmissive pulse oximetry. TST is defined as the total time asleep in minutes using PSG.
Measure: Mean SpO2 During TST on Day 1 and Day 8 of Treatment Time: OSA Cohort: Day 1 and Day 8; COPD Cohort: Day 1Description: SpO2 is an estimate of the amount of oxygen in the blood. It is the percentage of hemoglobin containing oxygen compared to the total amount of hemoglobin in the blood (that is, oxygenated hemoglobin versus oxygenated and non-oxygenated hemoglobin). SpO2 is monitored by noninvasive method known as transmissive pulse oximetry. TST is defined as the total time asleep in minutes using PSG.
Measure: Percentage of TST During Which the SpO2 is <90 percent (%), <85% and <80% on Day 1 and Day 8 of Treatment Time: Day 1 and Day 8Description: ODI is defined as (oxygen desaturations >=3%*60)/TST (that is, the average number of oxygen desaturations >=3% per hour of sleep), as defined by the American Academy of Sleep Medicine. ODI will be assessed using PSG.
Measure: Mean Oxygen Desaturation Index (ODI) on Days 1 and 8 of Treatment Time: Day 1 and Day 8Description: Desaturation is defined as decrease in the mean SpO2 of >=3% (over the last 120 seconds) that lasts for at least 10 seconds. Desaturation will be assessed using PSG.
Measure: Absolute Number of Desaturations (>=3% Reduction From Baseline SpO2) on Days 1 and 8 of Treatment Time: Day 1 and Day 8Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports